Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6964614 | 0.86 | TXN (0.54) | NPC1RAB9AKDM4EMAPTLMNA | |
| SCHEMBL3708228 | 0.86 | TAAR1 (0.61) | NPC1RAB9ACYP1A2KDM4EMAPT | |
| SCHEMBL9739272 | 0.81 | KMT2A (0.66) | CYP1A2CYP3A4CYP2C19KDM4EMAPT | |
| SCHEMBL9762921 | 0.80 | NPC1 (0.55) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17943198 | 0.79 | NPC1 (0.56) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL11630110 | 0.78 | KCNH3 (0.59) | NPC1RAB9AKDM4EMAPTLMNA | |
| SCHEMBL18037965 | 0.78 | KMT2A (0.73) | NPC1RAB9ACYP1A2MAPTCASP1 | |
| SCHEMBL9505657 | 0.77 | RAB9A (0.48) | NPC1RAB9ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL9123851 | 0.76 | KMT2A (0.43) | NPC1RAB9ACYP1A2KDM4ECASP1 | |
| SCHEMBL22628619 | 0.75 | RAB9A (0.65) | NPC1RAB9AKDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2398791-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | Amgen, Inc (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010096314-A1 | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS | AMGEN INC. (US) | 2010-08-26 | — | — | WO | disclosed |
| EP-0270111-B1 | PYRIMIDINE DERIVATIVES AND AGRICULTURAL OR HORTICULTURAL FUNGICIDAL COMPOSITION CONTANING THE SAME | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
| US-4992438-A | Pyrimidine derivatives, process for preparing the same and agricultural or horticultural fungicidal composition containing the same | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0270111-A1 | Pyrimidine derivatives and agricultural or horticultural fungicidal composition contaning the same | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-4256738-A | BACTERICIDES, PYRIMIDINYL, QUINAZOLINYL | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
| EP-0001981-A1 | 9-(Omega-heteroarylamino-alkylamino)-erythromycins, their salts, processes for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | NPC1 1929/4885RAB9A 2151/4885CYP1A2 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.